


It's never too

early




*to detect a relapse
or complication*



Discover

moovcare


By Sivan



Moovcare® is a web application that detects relapse or complication during follow-up of lung cancer patients.

A Class I Medical Device, Moovcare® has been proven in clinical trial to improve overall survival by 7.6 months¹

Who benefits?^{3,4}



Caregivers

- *Early detection*
- *Constant vigilance*
- *More treatment options*
- *Efficient intervention*
- *Better management of the medical visit*



Patient

- *Improved survival*
- *Reduced anxiety, improved QOL*
- *Constant communication with the caregiver*
- *Personalized follow-up*




Hospital

- *Fewer costly tests*
- *Reduced workload*
- *Reduced emergency hospitalization*
- *Better supportive care*

How does early detection improve survival?

The standard lung cancer follow-up is fundamentally flawed. Broadly spaced CT scans detect relapse and complication too late for patients, by which time their health has deteriorated and the limited treatment options available offer a suboptimal outcome.

Moovcare® dramatically improves survival by using a weekly patient questionnaire via an easy to use web app, to detect relapse or complication and immediately alert caregivers when there might be a anomaly.¹



A horizontal timeline diagram. A thick grey line runs across the middle. A black dot is placed on this line, with the letters 'CT' written below it. A vertical line descends from the dot to a small circle, which is connected to the text 'Standard lung cancer follow-up. Problem discovered weeks or months after event'. Below the grey line is a horizontal dotted yellow line. A vertical line descends from the start of this dotted line to a small circle, which is connected to a yellow rounded rectangle containing the text 'Moovcare® lung cancer follow-up. Caregiver alerted the moment a problem is detected'.

CT

Standard lung cancer follow-up. Problem discovered weeks or months after event

Moovcare® lung cancer follow-up. Caregiver alerted the moment a problem is detected

Relapses do not occur on the day of the CT scan. Two thirds of symptomatic patients wait for the CT scan to detect their symptoms. During this period, a patient's general condition degrades if not treated promptly.^{5,6}

The Moovcare® weekly follow-up enables detection at the first symptoms of relapse or complication thereby avoiding deterioration of the general state.

Moovcare® has proved to be an accurate tool with 100% sensitivity and 89% specificity.⁸

So how does early detection improve survival?


1. early detection of complications
2. prompt response prevents deterioration
3. optimal treatment
4. supportive care



Standard follow-up


- *Reactive approach*
- *Consultation and CT scan every 3-6 months*
- *Patient feels alone at home w/o communication with the caregiver between visits and have difficulties reaching their oncologist*
- *Patient experiences anxiety*
- *Patient is not aware of the symptoms*
- *Patient has limited time in their scheduled visit, tends to forget health conditions they experienced in the previous weeks and months*

Moovcare[®] follow-up



- ***Proactive and patient centric approach***
- ***Caregiver is updated on the patient's condition every week***
- ***Caregiver can optimize consultation and imaging exams according to need***
- ***Patient in constant communication with their caregiver***
- ***Patient experiences less anxiety and improved QOL***
- ***Patient becomes more aware of their symptoms***

A new paradigm in lung cancer follow-up



Clinically validated

Moovcare® has undergone six years of rigorous development and clinical validation, culminating in CE certification as a Class I medical device.

Final results from phase III multicentric prospective randomized trial, first presented at ASCO 2018, show an improvement in overall survival of 7.6 months and QOL.¹

CE Class I medical device



Results presented at

ASCO

Published in

JAMA **JNCI**

Deployed in the field

Moovcare® was launched as a pilot in Elsan healthcare centers, Institute Curie, CHU Lille and more private hospitals across France.

This year, additional pilots will be launched in France, Israel and USA.

International studies to extend Moovcare® to other indications, will be headed by Dr. Ethan Basch and Dr. Fabrice Denis.

At 1 year, the percentage of patients with a stabilized state (PS score of 0-1) at relapse was significantly higher in the SENTINEL* arm: 76.5% (n = 26) compared to the standard arm 33.3% (n = 26). = 12 (p <0.001)⁷

An optimal treatment was delivered in 74% of the patients with relapse of the experimental arm vs 32.5% of the patients in relapse of the control arm (p <0.001)⁷

* Moovcare® was previously named SENTINEL



Product pipeline

Moovcare® Lung is the first in a line of breakthrough medical devices developed by Sivan Innovation Ltd., in collaboration with leading oncologists. All devices monitor symptoms using web-based patient reported outcomes (PROs), which the company's clinically proven algorithms analyze to detect early signs of relapse, complication, or future medical risk.



Moovcare®
Lung



Moovcare®
All Cancer



ID of
high risk
populations



Other chronic
diseases

About Sivan

Sivan Innovation Ltd. has been at the forefront of eHealth innovation since 2014. As proponents of the efficacy of patient reported outcomes (PROs) in the early detection of disease, Sivan has built an all-star team to design, clinically validate, and develop commercial medical applications based on proprietary disease-specific algorithms. The company remains committed to supporting healthcare professionals, and improving patient care, life expectancy, and quality of life.

Board members:

Daniel ISRAEL, President & founder

Paul COHEN, CEO

Operational direction:

Ayala BLIAH, COO



Sivan

Talk to us

Sources:

1. F. Denis ASCO 2018 abstract 6500.
2. Denis F, Basch E, Septans A, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. *JAMA*. 2019;321(3):306–307. doi:10.1001/jama.2018.18085
3. Denis F et al. Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up. *Care cancer* 2014 Jan;22(1) 79-85
4. Denis F et al. Detection of lung cancer relapse using self-reported symptoms transmitted via an internet web-application: pilot study of the sentinel follow-up. *Support cancer care*. 2014 Jan;(22) 6:1467-73
5. Walsh GL et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? *Ann Thorac Surg*. 1995 Dec;60(6):1563-70
6. Westeel V et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. *Ann Thorac Surg*. 2000 Oct;70(4):1185-90
7. *J Natl Cancer Inst*. 2017;109(9): djx029
8. Denis F et al. Improving Survival in Patients Treated for a Lung Cancer Using Self-Evaluated Symptoms Reported Through a Web Application. *Am J Clin Oncol*. 2015 Mar 24.
9. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed on 05/19/2016)

Sivan headquarters

19 Hartom Street, Jerusalem

97775, Israel

contact@sivan-innovation.com

sivan-innovation.com

Sivan France

European representative

35 Boulevard Sebastopol,

75001, France



Sivan